‘Cancer vaccine’ boosts survival rates when combined with immunotherapy drugs in small study

doctor preparing vaccine shot

The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone, but that the benefit was still only a few months for two forms of cancer, study sponsor Neon Therapeutics reported on [July 15].

It was a hint that an experimental therapy often described as the next great hope for immune-based approaches to fighting cancer will not be a silver bullet.

In the study, the 21 patients with metastatic bladder cancer, and the 27 with metastatic non-small-cell lung cancer, had a median progression-free survival (PFS) of 5.6 months, meaning half saw their tumors grow or spread before that time.

The 34 metastatic melanoma patients did dramatically better: After 13.4 months, the PFS had not yet been reached. That is, fewer than half the patients had experienced cancer growth or further metastasis by that point.

By comparison, in clinical trials of the immunotherapy drugs called checkpoint inhibitors, median progression-free survival has been about two to four months in non-small cell lung, and two to three months in bladder cancer. 

Read full, original post: In a small study, a cancer vaccine assist beats immunotherapy drugs alone

Related article:  Viewpoint: Drug developers are abandoning current Alzheimer’s patients. Why is no one complaining?
Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: The evolutionary history of the COVID-19 coronavirus

Infographic: The evolutionary history of the COVID-19 coronavirus

Reuters analysed over 185,000 genome samples from the Global Initiative on Sharing All influenza Data (GISAID), the largest database of ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend